OIL (ASX) Tiresias: Whither current pathology?

Originally posted by Tiresias: ↑

“Taceant colloquia. Effugiat risus. Hi locus is est ubi mors Gaudet succurrere vitae.”
(Let idle talk be silenced. Let laughter be banished. This is the place where death rejoices to teach those who live.)
Inscription at the entrance to autopsy rooms.
"They never look very big on the tables, the bodies"
Yann Martel
My friends,
It may seem that Tiresias is in a morbid frame of mind this week. Not at all. Tiresias is equanimous. The blind Tiresias, you see, sees all too clearly. Current histopathologists need reassuring that glass microscope slide, ex-vivo, post-mortem histopathology, which in principle hasn’t changed since Leeuwenhoek and Koch, will go the way of the autopsy. You see, my friends, Tiresias studied medicine when the autopsy was last test, the final arbiter. Tiresias as a student, and young and not so young doctor, at the end of each ward round, would head trepidantly to the autopsy room, for the final post-mortem examination of the patients that doctors had treated and who had died. It was a standard practice that, unless there were some extreme reasons not to, all patients who died in hospital were autopsied. The autopsy was the final and often salutary arbiter, and often a very painful one, which revealed the real diagnosis and real cause of death.
In the last 30- or 40- years autopsy, across the whole western world has gone the way of the dodo. In Australia, except for coroners’ cases, autopsies are rarely done. This is a result of a number of factors but the most crucially, to the relief of the doctors, is the increase sophistication of medical imaging which reveals some the diagnostic enigmas antemortem, which were only available post-mortem. This gives the false comfort to the doctors and the bereaved, so they can say the autopsy will have nothing to add. Quite apart from the medical advances, which provide a fig leaf for not doing autopsies, social changes have made autopsies socially unacceptable, so there is a confederacy of “Don’t ask, don’t tell.” Which suits everyone. Besides, autopsies are expensive.
Tiresias then wonders. Tiresias wonders if the current practice of glass-slide, analogue, impressionistic, very expensive histopathology will go the way of the autopsy. With Confocal Laser Endomicroscopy (CLE), which provides in-vivo, real-time digital, cost and time efficient, AI assisted histopathology, the need to biopsy, with its delayed complex process, requiring excision of tissue and associated sampling problems; the technically complex and expensive process of preservation, slicing, staining, placement on slides, then examination under microscope, give impressionistic diagnosis, which is often wrong, and always too late. Tiresias would like to think that some of the pathology companies realise this about this nice little earner, and might start to take some insurance through Optiscan, and avoid their Kodak moment.

Expand

In reply to the Prophet’s post and with reference to a post dated 12/02/22 at titled Mauna Kea Technologies is not as good as Optiscanwhich stated:

Ex-vivo (outside the living body) --- Whilst Optiscan’s focus in on the living (human and animal) there is no reason why the technology cannot be used for post mortem tissue analysis. Perhaps the differentiation between Covid-19 and the influenza? I contend that the examination of cancers in a corpse may provide a useful base for an artificial intelligence (AI) database. As long as the tissue is preserved properly.

A couple of questions arise.

First, does medical equipment used in post mortems [an autopsy] require TGA or FDA approval in the relevant countries? Intuitively the answer is no but the relevant laws may capture it due to the wide scope for the definition of medical equipment. If no, then the Coroners Court of Victoria ( [email protected] ) and others in the country should have Optiscan’s InVivage or FIVE2 now!

Secondly, what is the feasibility, as an adjunct to post mortems, for the creation of a cancer image library using InVivage, that amongst other things can assist in the creation of an AI cancer database. Not forgetting images of normal tissue as well.

No.	Vol.	Price($)
1	11549	21.0¢

No.

Vol.

Price($)

11549

21.0¢

Price($)	Vol.	No.
22.0¢	45000	1

Price($)

Vol.

No.

22.0¢

45000

No.	Vol.	Price($)
1	11549	0.210
2	99732	0.205
3	54967	0.200
1	3000	0.195
5	69097	0.190

No.

Vol.

Price($)

11549

0.210

99732

0.205

54967

0.200

3000

0.195

69097

0.190

Price($)	Vol.	No.
0.220	45000	1
0.225	23850	2
0.230	350000	4
0.240	50000	1
0.245	25000	1

Price($)

Vol.

No.

0.220

45000

0.225

23850

0.230

350000

0.240

50000

0.245

25000

(20min delay)
Last 21.0¢		Change 0.005(2.44%)		Mkt cap ! $175.4M

Open	High	Low	Value	Volume
21.0¢	22.0¢	20.0¢	$170.8K	817.1K

Tiresias: Whither current pathology?, page-5

Sun Silver submits US$60M Silver Paste Funding Application to US DoE

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Time for retail therapy buying in the shopping Scentre for hot stocks

Eurozone-based companies find new ways to secure a regional lithium supply

End of FY is a time to juggle wins, losses and capital gains taxes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Tiresias: Whither current pathology?, page-5

Top Stories

Sun Silver submits US$60M Silver Paste Funding Application to US DoE

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Time for retail therapy buying in the shopping Scentre for hot stocks

Eurozone-based companies find new ways to secure a regional lithium supply

End of FY is a time to juggle wins, losses and capital gains taxes

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News